Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.

Narges Zare Mehrjardi, Daniel Hänggi, Ulf Dietrich Kahlert

Cell death & disease 2020 Nov 21

filter terms:

Isocitrate dehydrogenases (IDH1/2) are central molecular markers for glioblastoma. Providing in vitro or in vivo models with mutated IDH1/2 can help prepare facilities to understand the biology of these mutated genes as glioma markers, as well as help, improve therapeutic strategies. In this review, we first summarize the biology principles of IDH and its mutations and outline the core primary findings in the clinical context of neuro-oncology. Given the extensive research interest and exciting developments in current stem cell biology and genome editing, the central part of the manuscript is dedicated to introducing various routes of disease modeling strategies of IDH mutation (IDHMut) glioma and comparing the scientific-technological findings from the field using different engineering methods. Lastly, by giving our perspective on the benefits and limitations of patient-derived and donor-derived disease modeling respectively, we aim to propose leading research questions to be answered in the context of IDH1 and glioma.

Citation

Narges Zare Mehrjardi, Daniel Hänggi, Ulf Dietrich Kahlert. Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma. Cell death & disease. 2020 Nov 21;11(11):998